This podcast episode discusses the clinical use of antibody-drug conjugates (ADCs) in the treatment of endometrial cancer. The key highlights are:
Trastuzumab deruxtecan, a HER2-targeted ADC, has shown impressive response rates of 58% in recurrent endometrial cancer patients, with an 85% response rate in those with confirmed 3+ HER2 expression. This has led to its inclusion in the NCCN guidelines for endometrial cancer.
The use of trastuzumab deruxtecan requires careful monitoring for potential toxicities, particularly interstitial lung disease, which can be a serious adverse event. Pathologists play a crucial role in accurately determining HER2 expression levels to guide appropriate patient selection.
Beyond trastuzumab deruxtecan, there are other promising HER2-directed ADCs in development, such as BNT323/DB-1303 from BioNTech, which are exploring broader biomarker criteria (e.g., including HER2 1+) to expand the eligible patient population.
Additional targets for ADCs in endometrial cancer include FOLR1, TROP-2, B7-H4, and CDH6. Combination strategies with DNA damage response inhibitors are also being investigated to potentially enhance the efficacy of these ADCs.
The rapid progress in ADC development for endometrial cancer represents an exciting new era, with the potential to transform outcomes for patients who have historically had limited treatment options, especially in the recurrent setting.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Ursula A. Ma... at www.medscape.com 06-25-2024
https://www.medscape.com/viewarticle/999848Deeper Inquiries